Anavex Life Sciences Corp (AVXL)

[UnderVerse]

About PIII 2-73 TRIALS and funding for continued operations, per their IR:

Thank you for your email and support of Anavex Life Sciences Corp. (Nasdaq: AVXL).



Anavex has stated that it is planning a larger Phase 2/3 trial of ANAVEX 2-73 however the timing, location(s), enrollment criteria and other details have not been announced.



To remain up to date, we suggest subscribing to the Anavex email list if you have not already done so, which you can do by completing the form at the bottom right corner of any page on the company's website: www.anavex.com.



Contact information for recruitment sites as well as enrollment and exclusion criteria will be made available via www.clinicaltrials.gov in the future.



Anavex reported cash and cash equivalents of $17.3 million as of December 12, 2016. During the conference call that same day, Dr. Missling said that the company’s cash position will allow it to run for approximately two years without requiring additional cash.



Please do not hesitate to contact our office if we can be of further assistance.



On behalf of Anavex Life Sciences Corp.,



Investor Relations

Toll Free (North America): 1 [phone]

Outside North America: [phone]

Fax: [phone]

[e-mail]